PTC Therapeutics SG&A Expenses 2012-2024 | PTCT

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

PTC Therapeutics sg&a expenses from 2012 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

PTC Therapeutics sg&a expenses from 2012 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$79.2B
Takeda Pharmaceutical (TAK)	$43.3B
Sandoz Group AG (SDZNY)	$19.5B
Merck (MKKGY)	$19.2B
Astellas Pharma (ALPMY)	$18.2B
United Therapeutics (UTHR)	$16.1B
Summit Therapeutics (SMMT)	$14.7B
Neurocrine Biosciences (NBIX)	$12.1B
Shionogi (SGIOY)	$11.9B
Catalent (CTLT)	$10.7B
Jazz Pharmaceuticals (JAZZ)	$7.1B
Madrigal Pharmaceuticals (MDGL)	$6.9B
Orion OYJ (ORINY)	$6.7B
Corcept Therapeutics (CORT)	$5.7B
Ionis Pharmaceuticals (IONS)	$5.3B
Crinetics Pharmaceuticals (CRNX)	$5.1B
Dyne Therapeutics (DYN)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
Arrowhead Pharmaceuticals (ARWR)	$2.3B
Soleno Therapeutics (SLNO)	$2.2B
NewAmsterdam Pharma (NAMS)	$2.2B
Centessa Pharmaceuticals (CNTA)	$1.9B
Evotec AG (EVO)	$1.8B
Recursion Pharmaceuticals (RXRX)	$1.8B
Xencor (XNCR)	$1.7B
BioCryst Pharmaceuticals (BCRX)	$1.5B
Indivior (INDV)	$1.4B
Harrow (HROW)	$1.4B
Ocular Therapeutix (OCUL)	$1.4B